These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38833322)

  • 21. Perspective on Precision Medicine in Oncology.
    Johnson TM
    Pharmacotherapy; 2017 Sep; 37(9):988-989. PubMed ID: 28632968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genomics and bioinformatics as pillars of precision medicine in oncology.
    Canzoneri R; Lacunza E; Abba MC
    Medicina (B Aires); 2019; 79(Spec 6/1):587-592. PubMed ID: 31864231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiomics subtyping for clinically prognostic cancer subtypes and personalized therapy: A systematic review and meta-analysis.
    Ayton SG; Pavlicova M; Robles-Espinoza CD; Tamez Peña JG; Treviño V
    Genet Med; 2022 Jan; 24(1):15-25. PubMed ID: 34906494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioinformatics in urology - molecular characterization of pathophysiology and response to treatment.
    Hashemi Gheinani A; Kim J; You S; Adam RM
    Nat Rev Urol; 2024 Apr; 21(4):214-242. PubMed ID: 37604982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Breast cancer research in the era of precision medicine].
    Yang HY; Jiang YZ; Shao ZM
    Zhonghua Zhong Liu Za Zhi; 2016 Jun; 38(6):401-3. PubMed ID: 27346395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integration of Genomic Profiling and Organoid Development in Precision Oncology.
    Yoon H; Lee S
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathway Analysis for Cancer Research and Precision Oncology Applications.
    La Ferlita A; Alaimo S; Ferro A; Pulvirenti A
    Adv Exp Med Biol; 2022; 1361():143-161. PubMed ID: 35230687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer genomics and clinical practice: how can we close the gap more quickly?
    Konecny GE
    Curr Opin Obstet Gynecol; 2017 Feb; 29(1):1-3. PubMed ID: 27941363
    [No Abstract]   [Full Text] [Related]  

  • 29. The Architecture of a Precision Oncology Platform.
    Laganà A
    Adv Exp Med Biol; 2022; 1361():1-22. PubMed ID: 35230680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Moving toward precision medicine to predict drug sensitivity in patients with metastatic breast cancer.
    Bottosso M; Mosele F; Michiels S; Cournède PH; Dogan S; Labaki C; André F
    ESMO Open; 2024 Mar; 9(3):102247. PubMed ID: 38401248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer.
    Rashid NU; Peng XL; Jin C; Moffitt RA; Volmar KE; Belt BA; Panni RZ; Nywening TM; Herrera SG; Moore KJ; Hennessey SG; Morrison AB; Kawalerski R; Nayyar A; Chang AE; Schmidt B; Kim HJ; Linehan DC; Yeh JJ
    Clin Cancer Res; 2020 Jan; 26(1):82-92. PubMed ID: 31754050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Precision treatment exploration of breast cancer based on heterogeneity analysis of lncRNAs at the single-cell level.
    Zhang Y; Zhang D; Meng Q; Liu Z; Xie H; Liu L; Xu F; Chen X
    BMC Cancer; 2021 Aug; 21(1):918. PubMed ID: 34388989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer molecular markers: A guide to cancer detection and management.
    Nair M; Sandhu SS; Sharma AK
    Semin Cancer Biol; 2018 Oct; 52(Pt 1):39-55. PubMed ID: 29428478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic.
    Prudkin L; Nuciforo P
    Cell Oncol (Dordr); 2015 Feb; 38(1):39-48. PubMed ID: 25185990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pilot studies for personalized cancer medicine: focusing on the patient for treatment selection.
    De Mattos-Arruda L; Rodon J
    Oncologist; 2013; 18(11):1180-8. PubMed ID: 24136009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Precision oncology based on omics data: The NCT Heidelberg experience.
    Horak P; Klink B; Heining C; Gröschel S; Hutter B; Fröhlich M; Uhrig S; Hübschmann D; Schlesner M; Eils R; Richter D; Pfütze K; Geörg C; Meißburger B; Wolf S; Schulz A; Penzel R; Herpel E; Kirchner M; Lier A; Endris V; Singer S; Schirmacher P; Weichert W; Stenzinger A; Schlenk RF; Schröck E; Brors B; von Kalle C; Glimm H; Fröhling S
    Int J Cancer; 2017 Sep; 141(5):877-886. PubMed ID: 28597939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Signature Program: Bringing the Protocol to the Patient.
    Kang BP; Slosberg E; Snodgrass S; Lebedinsky C; Berry DA; Corless CL; Stein S; Salvado A
    Clin Pharmacol Ther; 2015 Aug; 98(2):124-6. PubMed ID: 25810246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blueprint for cancer research: Critical gaps and opportunities.
    Elmore LW; Greer SF; Daniels EC; Saxe CC; Melner MH; Krawiec GM; Cance WG; Phelps WC
    CA Cancer J Clin; 2021 Mar; 71(2):107-139. PubMed ID: 33326126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RNA sequencing for research and diagnostics in clinical oncology.
    Buzdin A; Sorokin M; Garazha A; Glusker A; Aleshin A; Poddubskaya E; Sekacheva M; Kim E; Gaifullin N; Giese A; Seryakov A; Rumiantsev P; Moshkovskii S; Moiseev A
    Semin Cancer Biol; 2020 Feb; 60():311-323. PubMed ID: 31412295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor immune dysfunction and exclusion subtypes in bladder cancer and pan-cancer: a novel molecular subtyping strategy and immunotherapeutic prediction model.
    Zheng K; Hai Y; Chen H; Zhang Y; Hu X; Ni K
    J Transl Med; 2024 Apr; 22(1):365. PubMed ID: 38632658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.